In prior research, we developed a claims-based prediction model for poor patient disability status (DS), a proxy measure for performance status, commonly used by oncologists to summarize patient functional status and assess ability of a patient to tolerate aggressive treatment. In this study, we implemented and validated the DS measure in 4 cohorts of cancer patients: early and advanced non-small cell lung cancers (NSCLC), stage IV estrogen receptor-negative (ER À) breast cancer, and myelodysplastic syndromes (MDS).
M easurement and control for relevant dimensions of health status represent key challenges in observational studies of treatment and outcomes using administrative claims data. There are a variety of comorbidity measures based on the presence of selected International Classification of Diseases, revision 9, clinical modification (ICD-9-CM) diagnosis codes. 1, 2 Other dimensions of health status may be equally important, yet are difficult to measure from claims. 3, 4 Performance status (PS) is commonly used in oncology practice to measure patients' functional capacity, with an emphasis on physical dimensions. 5 Because of its prognostic value for survival, PS is often a key factor in determining whether cancer patients are healthy enough to tolerate surgery or aggressive chemotherapy that may be recommended for a given disease and stage. 6, 7 Given the clinical importance of PS in making treatment decisions for cancer patients, we previously developed a multivariate prediction model based on administrative claims to capture this dimension of health status. 8 Data were obtained from the Medicare Current Beneficiary Survey (MCBS), a nationally representative survey of communitybased and institutionalized Medicare beneficiaries linked to Medicare claims. 9 Our dependent variable, a proxy measure for PS referred to as disability status (DS), was based on selfreported functional status information collected during the MCBS. The explanatory variables in our model were indicators for health care services used more or less commonly in persons with poor DS (see the online appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/ A696 for additional detail on the PS scale, the DS model, and development). Applying the results of our prediction model in the MCBS, we found that predicted poor DS was strongly associated with worse survival.
Given the initial results in development of the DS model and validation of DS within a general Medicare population, we sought to evaluate the predicted DS measure in a cancer-specific sample, and examine whether the addition of information on DS enhances the ability to explain receipt of cancer treatment. We used Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare enrollment and claims data, 10 and selected 4 previously studied cohorts of older Medicare beneficiaries with cancer. The 4 study cohorts and the treatments examined were: (1) surgical resection for early-stage (stages I or II) non-small cell lung cancer (NSCLC); (2) chemotherapy for advanced stage (stage IIIB with pleural effusion or stage IV) NSCLC (AdvNSCLC) 11 ; (3) chemotherapy for stage IV (metastatic) estrogen receptor-negative (ERÀ) breast cancer 12 ; and (4) erythropoiesis-stimulating agent (ESA) use for myelodysplastic syndromes (MDS). 13 These 4 cohorts were selected because they illustrate different disease processes and prognosis, types of treatment, and the potential role of PS in determining treatment. Early-stage NSCLC is a condition for which surgical intervention has curative potential, whereas AdvNSCLC and breast cancer are not curable, although chemotherapy offers survival benefit and symptom palliation. 14, 15 For each of these, the treatment may be contraindicated in a patient with poor PS. Finally, MDS are a group of hematopoietic stem cell neoplasms commonly associated with symptomatic anemia. Despite the availability of newer disease-modifying treatments, many MDS patients receive chronic ESAs as a component of clinical management. Although there is no evidence that ESA use modifies survival, it is associated with improved quality of life. [16] [17] [18] While ESAs are not contraindicated for individuals with poor PS, poor PS may interfere with the ability to travel to a physician office to receive therapy.
For each disease cohort, we sought to address 3 aims. First, we examined whether patient age, socioeconomic status, and selected other characteristics were correlated with poor DS. Prior research suggests that various patient demographic and socioeconomic characteristics are associated with poor functional status. 19, 20 A strong correlation between these patient characteristics and predicted DS would provide convergent validation. Second, we evaluated the ability of DS to explain whether patients received the designated cancer treatment, which would provide predictive validation. In the third aim, we sought to evaluate the predicted DS measure in a cancer-specific sample, and examine whether the addition of information on DS enhances the ability to explain the receipt of cancer treatment compared to models with or without the Charlson Comorbidity Index (CCI) and with controls for sociodemographic variables. 21 The CCI, commonly used in cancer-specific studies, identifies the presence of diagnoses for any of 19 conditions and creates a weighted index reflecting the contribution of those conditions to 1-year non-cancer-related mortality.
METHODS

Study Population
Patients in each cohort were selected from the National Cancer Institute's SEER-Medicare database. SEER comprises data from 16 regional cancer registries, and includes information on selected patient demographics and clinical characteristics, including cancer site, histology, and date of diagnosis. For Medicare beneficiaries, SEER data are linked to Medicare enrollment and claims (Parts A and B) files, which contain additional information on the use of specific healthrelated services and therapies, as well as patients' date of death.
Selection criteria for 3 of the cohorts have been described previously [11] [12] [13] and are summarized for all 4 cohorts in Table 1 . Common inclusion and exclusion criteria were designed to ensure completeness of key data elements and Medicare claims. In addition, each cohort had disease-specific exclusion criteria that had been implemented as part of the prior studies.
Measures
The key outcome measure for each cohort was a dichotomous indicator for receipt of the designated cancerdirected treatment. Treatments were measured based on either initial cancer-related therapy reported through the SEER registry data or from ICD-9-CM procedures codes, Healthcare Common Procedure Codes, and/or National Drug Codes culled from Medicare Part B claims. The treatments considered were: (1) surgical resection for early-stage NSCLC; (2) chemotherapy received within 90 days of diagnosis for AdvNSCLC; (3) chemotherapy received within 6 months of diagnosis for breast cancer; and (4) receipt of ESAs any time post-MDS diagnosis.
Common sociodemographic characteristics from the SEER-Medicare database are listed in Table 1 , as are cohortspecific covariates, such as disease stage or risk group.
We incorporated 2 measures to capture baseline health status. First, we applied the Deyo adaptation 22 of the CCI, modified to exclude cancer diagnoses, to Medicare inpatient, outpatient, and physician claims during the 12-month period before cancer diagnosis. We categorized CCI into 4 groups (0, 1, 2, or Z3) based on the initial distribution. Second, we generated patient-specific predictions for poor DS. The process involved constructing the health care service predictors used in our DS model from Medicare claims from the 12 months before each cancer diagnosis date linked to members of each disease cohort. We applied the estimated regression coefficients from the model to the set of constructed measures for each observation to generate a predicted probability of poor DS. The predicted DS values ranged from 0 to 1, with high values representing a high probability of poor DS. We converted the continuous predicted probability of poor DS into quartile ranges to create a categorical measure of poor DS. For this measure, quartile 1 was the lowest probability of poor DS (highest probability of good DS), whereas quartile 4 was the highest probability of poor DS. In the DS model development phase, we considered models that permitted interactions between selected variables (ie, region, year, and Medicaid) and the specific service indicators. In this paper, we focus only on the model without interactions. In sensitivity analyses, we also examined results for predicted DS measures based on the models with interactions, but did not find Had other primary cancer within 5 y before MDS diagnosis AML indicates acute myeloid leukemia; CML, chronic myeloid leukemia; CMMoL, chronic myelomonocytic leukemia; ER À, estrogen receptor-negative; NSCLC, non-small cell lung cancer; RA, refractory anemia; RAEB, RA with excess blasts; RAEB-t, RA with excess blasts in transformation; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia. 
Statistical Analysis
Bivariate analyses using w 2 tests examined the association between the categorical measure of predicted poor DS and selected patient characteristics and receipt of primary treatment for each disease cohort. Multivariate logistic regression models were used to explain receipt of recommended cancer treatment, as well as examine how estimated associations and model fit varied based on the inclusion or exclusion of DS and/or CCI. Results for the C statistic, and treatment prediction (using a 0.5 probability as the cut-point to distinguish treated from untreated) were calculated to assess model fit. We also calculated the integrated discrimination improvement (IDI) measure, which combines information on changes in sensitivity and specificity of the predictions associated with a new explanatory variable, and is more sensitive than the C statistic. 23, 24 For each disease cohort, we estimated multiple models. Specifically, we estimated adjusted models that included either DS only (model 1), CCI only (model 2), or both (model 3), with controls for a variety of patient demographic and disease-specific measures. We also estimated a model (model 4) that included these covariates only, but neither DS nor CCI. We used model 4 as the reference case for calculating the IDI.
RESULTS
Patient characteristics for each study cohort are presented in Table 2 . The distributions of CCI between early-stage NSCLC (n = 20,280), AdvNSCLC (n = 31,341), and MDS (n = 6058) were similar, with more than half of patients presenting with a CCI of 1 or greater in the 12 months before diagnosis. For breast cancer (n = 1519), almost 64% of patients had a CCI = 0. The median values for predicted poor DS were 1.8, 2.5, 6.0, and 1.8 for the early-stage and AdvNSCLC, breast cancer, and MDS cohorts, respectively.
For both early-stage and AdvNSCLC, and use of ESAs for MDS, poor DS was associated with all patient demographic and socioeconomic characteristics examined. Results were similar for breast except that residence and region of the country were not significant. Table 3 reports the associations between each characteristic and the highest probability quartile of poor DS. Women, nonwhites, patients not currently married, and patients with prior year Medicaid were more likely, whereas individuals with higher area income and educational attainment were less likely to be in the top quartile. Of particular interest is the finding of a nonmonotonic relationship between age and DS. In all 4 disease groups, the proportion in the highest DS quartile was higher for age group 66-69 compared to ages 70-74, but then increased again in a monotonic manner from ages 75 to 79 upward for early-stage NSCLC and from ages 70 to 74 upward for the other 3 disease groups. As CCI increased, the proportion in the top quartile of poor DS also increased monotonically for AdvNSCLC, breast, and MDS, whereas there was a slight deviation from the pattern for early-state NSCLC. Table 4 reports receipt of recommended cancer treatment for each cohort overall and stratified by predicted DS, Table 5 presents the results of multivariate logistic regression models, by disease, for the association between predicted poor DS and receipt of recommended cancer-directed treatment. We report only the results associated with DS and CCI, the model fit statistics, including the IDI, and the treatment model predictive ability. The full model results are presented for each disease cohort in Appendix Tables 2-5 Higher probability of poor DS was associated with lower odds of recommended treatment for early-stage and AdvNSCLC, respectively, both with and without CCI in the model. In model 3, the odds of receiving treatment in DS quartile 4 (ie, highest probability of poor DS) were 77% and 72% less than the odds of treatment in DS quartile 1 for early-stage and AdvNSCLC, respectively (P < 0.05). Results were similar for prediction of treatment in breast cancer and MDS, although in most of the adjusted models, the difference between the 2 lowest DS quartiles was not significant. In model 3, the odds of receiving treatment in DS quartile 4 were 60% and 67% less than the odds of treatment in DS quartile 1 for breast cancer and MDS, respectively (P < 0.05). In all these models, the odds of receiving treatment decreased with increasing probability of poor DS.
In the adjusted models, the C statistic and sensitivity, specificity, and positive and negative predictive values did not vary substantially by whether DS, CCI, or both were included in the models. The IDI indicates that relative to a model with just the covariates, the addition of each health status measure contributes significantly to model improvements, but the magnitudes were small. For example, in earlystage NSCLC, treatment model sensitivity estimates ranged from 88.1 to 89.0, with the highest value for model 4-the model with covariates only, while specificity was highest in the models with DS. The C statistics were 0.83, 0.81, and 0.83 for adjusted models with DS, CCI, and both, respectively. The specific patterns differed across disease cohorts, with C statistics ranging from 0.83 in early-stage NSCLC to 0.66 for MDS. The differences across diseases likely relate to differences in the underlying treatment rates and the degree to which observable characteristics can explain treatment patterns.
CONCLUSIONS
The study results provide strong support for the validity of DS as a measure that can be used in claims-based studies to add information on health status. DS was strongly correlated with several patient characteristics associated with functional status, such as age and socioeconomic status, providing convergent validation for the measure. In addition, DS was a significant predictor of cancer treatment in all 4 cohorts; in each cohort, a higher probability of poor DS was associated with lower probability of receiving recommended cancer therapy, providing predictive validation. DS remained significant in each model even with the addition of CCI, suggesting that it captures a different dimension of health status, 25 and that both can be incorporated as health status controls. This validation research builds on an initial validation, which demonstrated that predicted poor DS was associated with mortality risk within a general Medicare population, and that the association remained even with controls for CCI. 8 There is an extensive literature that examines the prevalence of comorbidity and the association between comorbidity and receipt of cancer treatment. [26] [27] [28] The measures of health conditions in claims-based studies derive from the presence of ICD-9 diagnosis codes identified from claims, either individually or as an index, such as the CCI. 1, 2, 4 Increasing comorbidity burden is almost always associated with reduced probability of treatment, as we found in our study. The unique contribution of the DS measure is that it allows for the role of functional status to be examined as a predictor of treatment or in stratification of study samples. The ultimate goal of developing the DS measure was to improve covariate control for health status, with the expectation that inclusion of DS would reduce potential confounding between cancer treatment and outcomes in claims-based comparative effectiveness research studies. 8 As a necessary first step, we sought to demonstrate that the addition of DS would improve the ability to predict or explain cancer treatment. Hence, the positive results indicating that DS is a significant and independent predictor of cancer treatment (our second aim) are tempered by our finding that the addition of DS to the treatment models did not substantially improve model fit. Although the IDI results suggested significant improvement, the magnitude of the effect was small, and the other fit statistics also demonstrated only small movement across models. In fact, relative to the model with only demographic and socioeconomic covariates, neither the addition of DS nor CCI resulted in large changes in model fit. Although we did not expect that the addition of DS would completely eliminate unexplained variation in treatment, a larger effect would have offered greater expectation of reduced confounding for downstream research examining outcomes associated with cancer treatment. Additional refinements to the DS model and measure might further improve on the predictive ability, but it is unlikely that improvements would be dramatic.
The failure of DS to improve treatment model fit suggests that other factors, such as patient-physician communication, social supports, or financial resources, are important, yet unobserved determinants of treatment. 26 Unless claims datasets used in outcomes research are enhanced further with survey information on these dimensions, there will be an ongoing need to develop and refine analytic strategies that address confounding by unobserved confounders. One approach is to use propensity score analysis to address confounding by observable factors that affect both the probability of specific treatments and survival. 29, 30 Although propensity score methods have been widely used to study cancer treatment [31] [32] [33] [34] they only control for observed factors that affect treatment choice, and cannot address bias associated with unobserved characteristics. An alternative approach is to use instrumental variable analysis, [35] [36] [37] an econometric technique that is designed to remove the effects of treatment selection based on factors that cannot be observed in the data. Under the right conditions, instrumental variable estimation produces consistent estimates of the effects of treatment on outcomes, and has been used in a number of comparative effectiveness studies of cancer treatments. 33, 38, 39 However, finding an appropriate instrumental variable is often difficult, the estimates may vary depending on the instrument chosen, 40 and the estimates often lack precision. 41, 42 Hence, further development of the method is warranted.
The limitations of the study are principally those associated with use of claims data. Concerns have been raised about underreporting of services provided, but validation studies have established the high reporting rates for chemotherapy treatment. 43 We anticipate that this would be the case for surgical procedures and ESA use, as well. The study examines the role of DS in 4 diverse cohorts of cancer patients. Although it is possible that magnitude and significance of the effects of DS might differ for other cancer sites and stages, we are confident that the overall patterns would persist. Finally, this study examines the role of DS in predicting cancer treatment, but does not explicitly examine the potential role of DS in reducing confounding between cancer treatment and outcomes. This is an area of ongoing research.
DS appears to be a strong predictor of cancer treatment, independent of CCI. From that perspective, it is an important covariate to include in cancer treatment models. However, inclusion of DS did not substantially improve the fit of cancer treatment models as measured by their ability to predict who received treatment. This suggests that, even after controlling for DS, unobserved factors remain that may be important predictors of treatment and potential confounders in claims-based cancer outcomes research.
